Boston Scientific Sets Financial Goals, Long-term Growth Strategies at Investor Day.

• Boston Scientific to host Investor Day on Sept. 30, 2025 • Hybrid format with online webcast and registration • Replay and summary materials available on company website • Q3 earnings call on Oct. 22, 2025 at 8:00 a.m. ET • CEO Mike Mahoney and CFO Jon Monson to host call • Financial results and business highlights to be discussed • Webcast available on company investor website.

Boston Scientific Corporation (NYSE: BSX) has announced its upcoming Investor Day and Q3 earnings call for the year 2025. The Investor Day will be held on Tuesday, September 30, 2025, at 8:30 a.m. ET, and will be available in a hybrid format with an online webcast. This event will provide an opportunity for investors and other interested parties to review the company's financial goals and long-term growth strategies.

The Investor Day will be hosted in a hybrid format, allowing for both in-person attendance and remote participation through an online webcast. Investors can register for the webcast by visiting the events section on the company's investor website at [https://investors.bostonscientific.com](https://investors.bostonscientific.com). Replay and summary materials from the presentations will be available online on the website for approximately one year following the event.

Additionally, on Wednesday, October 22, 2025, at 8:00 a.m. ET, the company will host its Q3 earnings call. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the third quarter on October 22 prior to the conference call. A live webcast and replay for the event will be accessible at [https://investors.bostonscientific.com](https://investors.bostonscientific.com). The replay will be available approximately one hour following the completion of the event.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company's portfolio includes devices for diagnosing and treating gastrointestinal, pulmonary, urological, neurological, and other conditions. The company's latest earnings report indicated a strong performance, with quarterly earnings of $0.75 per share and revenue growth of 22.8% year-over-year to $5.06 billion [1].

Investors are encouraged to participate in these events to gain insights into the company's financial performance and future growth prospects. For more information, visit the company's investor website at [https://investors.bostonscientific.com](https://investors.bostonscientific.com).

References:

[1] https://www.marketbeat.com/instant-alerts/boston-scientific-corporation-nysebsx-given-consensus-recommendation-of-buy-by-brokerages-2025-08-26/